Condition
Prurigo
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (2)
P 3 (1)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05755438Phase 3CompletedPrimary
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
NCT02174432Phase 2Completed
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
NCT02174419Phase 2Completed
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
NCT03340155Not ApplicableUnknown
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
Showing all 4 trials